Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15855MR)

This product GTTS-WQ15855MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15855MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11284MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ4043MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ5049MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ5002MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ11245MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ1742MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ5038MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ8967MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW